为65岁及以上成人使用额外一剂2023-2024年更新版COVID-19疫苗:美国免疫实践咨询委员会建议——美国,2024年
尽管COVID-19相关重症总体下降,但住院负担仍集中在65岁及以上成人,2023年10月至2024年1月该人群占所有COVID-19相关住院的67%。ACIP于2024年2月28日建议所有65岁及以上成人接种1剂额外更新版(2023-2024配方)COVID-19疫苗,以增强可能已减弱的免疫力并降低重症和死亡风险。
要点
- 2023年10月至2024年1月,65岁及以上成人占所有COVID-19相关住院的67%。
- 2024年2月28日ACIP建议所有65岁及以上成人接种1剂额外更新版(2023-2024配方)COVID-19疫苗。
- 该建议基于SARS-CoV-2全年持续传播、该人群重症风险增高及疫苗保护预期减弱。
核心结论
- ACIP建议所有65岁及以上成人接种1剂额外更新版(2023-2024配方)COVID-19疫苗,以增强可能已减弱的免疫力并降低重症和死亡风险。
研究设计与样本
- 美国CDC免疫实践咨询委员会(ACIP)基于COVID-19流行病学与疫苗保护数据提出的建议。
主要发现
- 2023年10月至2024年1月,67%的COVID-19相关住院发生在65岁及以上成人中。
- 65岁及以上成人的COVID-19相关住院率高于较年轻成人、青少年和儿童。
- 2023年9月12日ACIP建议所有6月龄及以上人群接种更新版(2023-2024配方)单价XBB.1.5衍生COVID-19疫苗。
- SARS-CoV-2全年持续传播,且更新版疫苗对JN.1及其他流行变异株提供保护,疫苗诱导的保护预期会减弱。
关键数值与推荐
- 2024年2月28日ACIP建议所有65岁及以上成人接种1剂额外更新版(2023-2024配方)COVID-19疫苗。
- 2023年9月12日ACIP建议所有6月龄及以上人群接种更新版(2023-2024配方)单价XBB.1.5衍生COVID-19疫苗。
临床怎么用
- 落实ACIP建议可为65岁及以上成人接种1剂额外更新版(2023-2024配方)COVID-19疫苗,以增强可能已减弱的免疫力并降低重症和死亡风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19 remains an important public health threat, despite overall decreases in COVID-19-related severe disease since the start of the COVID-19 pandemic. COVID-19-associated hospitalization rates remain higher among adults aged ≥65 years relative to rates in younger adults, adolescents, and children; during October 2023-January 2024, 67% of all COVID-19-associated hospitalizations were among persons aged ≥65 years. On September 12, 2023, CDC's Advisory Committee on Immunization Practices (ACIP) recommended updated (2023-2024 Formula) COVID-19 vaccination with a monovalent XBB.1.5-derived vaccine for all persons aged ≥6 months to protect against severe COVID-19-associated illness and death. Because SARS-CoV-2 continues to circulate throughout the year, and because of the increased risk for COVID-19-related severe illness in persons aged ≥65 years, the protection afforded by updated vaccines against JN.1 and other currently circulating variants, and the expected waning of vaccine-conferred protection against disease, on February 28, 2024, ACIP recommended all persons aged ≥65 years receive 1 additional dose of the updated (2023-2024 Formula) COVID-19 vaccine. Implementation of these recommendations is expected to enhance immunity that might have waned and decrease the risk for severe COVID-19-associated outcomes, including death, among persons aged ≥65 years.
引用
- Panagiotakopoulos L, Godfrey M, Moulia DL, et al. Use of an Additional Updated 2023-2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024. PMID: 38662708. doi:10.15585/mmwr.mm7316a4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。